Fig.1From: Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitusChange from baseline in asprosin, body weight, body mass index (BMI), glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels in the sodium–glucose transporter-2 (SGLT2) inhibitors and placebo group at baseline, 12 weeks and 24 weeks. *P < 0.01, **P < 0.001Back to article page